enVVeno Medical Corporation (NVNO)
Largest Insider Buys in Sector
NVNO Stock Price History Chart
NVNO Stock Performance
About enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed …
Insider Activity of enVVeno Medical Corporation
Over the last 12 months, insiders at enVVeno Medical Corporation have bought $54,939 and sold $51,837 worth of enVVeno Medical Corporation stock.
On average, over the past 5 years, insiders at enVVeno Medical Corporation have bought $57,940 and sold $419,437 worth of stock each year.
Highest buying activity among insiders over the last 12 months: BERMAN ROBERT ANDREW (Chief Executive Officer) — $91,800. Jenusaitis Matthew (director) — $24,339.
The last purchase of 9,620 shares for transaction amount of $24,339 was made by Jenusaitis Matthew (director) on 2024‑12‑19.
List of Insider Buy and Sell Transactions, enVVeno Medical Corporation
| 2024-12-19 | Chief Executive Officer | 12,000 0.0687% | $2.55 | $30,600 | +0.59% | |||
| 2024-12-19 | director | 9,620 0.0546% | $2.53 | $24,339 | 0.00% | |||
| 2024-03-13 | Sale | Chief Technology Officer | 8,334 0.0626% | $6.22 | $51,837 | -21.56% | ||
| 2022-08-16 | 7,751 0.0731% | $6.14 | $47,591 | -11.21% | ||||
| 2022-06-30 | 1,000 0.0091% | $3.85 | $3,850 | +39.42% | ||||
| 2022-06-27 | Chief Executive Officer | 2,500 0.0221% | $3.80 | $9,500 | +37.42% | |||
| 2020-08-21 | Sale | 75,000 0.1713% | $0.38 | $28,500 | -35.13% | |||
| 2020-08-20 | Sale | 75,000 0.1995% | $0.27 | $20,250 | +6.30% | |||
| 2020-08-19 | Sale | 50,000 0.138% | $0.30 | $15,000 | -1.26% | |||
| 2020-08-18 | Sale | 50,000 0.1493% | $0.34 | $17,000 | -5.17% | |||
| 2020-08-14 | Sale | 50,000 0.1353% | $0.31 | $15,500 | -5.05% | |||
| 2020-08-03 | Sale | 70,000 0.1916% | $0.32 | $22,400 | -4.48% | |||
| 2020-07-31 | Sale | 5,000 0.0143% | $0.34 | $1,700 | -5.58% | |||
| 2020-07-30 | Sale | 25,000 0.0691% | $0.32 | $8,000 | -2.40% | |||
| 2020-07-21 | Sale | 50,000 0.1415% | $0.45 | $22,500 | -27.93% | |||
| 2020-07-20 | Sale | 150,000 0.4083% | $0.43 | $64,500 | -27.32% | |||
| 2020-07-17 | Sale | 50,000 0.1317% | $0.38 | $19,000 | -20.10% | |||
| 2020-07-16 | Sale | 50,000 0.1413% | $0.38 | $19,000 | -14.14% | |||
| 2020-07-06 | Sale | 6,450 0.0173% | $0.39 | $2,516 | -19.58% | |||
| 2020-07-02 | Sale | 57,000 0.1505% | $0.40 | $22,800 | -22.72% |
Insider Historical Profitability
| BERMAN ROBERT ANDREW | Chief Executive Officer | 222236 1.2673% | $2.82 | 2 | 0 | +37.42% |
| Jenusaitis Matthew | director | 16545 0.0943% | $2.82 | 1 | 0 | |
| Duhay Francis | 20911 0.1192% | $2.82 | 1 | 0 | <0.0001% | |
| Shrivastava Sanjay | 3888 0.0222% | $2.82 | 1 | 0 | +39.42% |
Institutional Investor Ownership
| Kingdon Capital Management | $3.56M | 4.91 | 653,870 | +5.6% | +$188,713.61 | 0.47 | |
| Perceptive Advisors | $3.39M | 4.68 | 623,315 | 0% | +$0 | <0.01 | |
| The Vanguard Group | $3.12M | 4.31 | 573,955 | +70.61% | +$1.29M | <0.0001 | |
| Nantahala Capital Management Llc | $2.7M | 3.72 | 495,736 | -29.81% | -$1.15M | 0.13 | |
| Ubs Oconnor Llc | $1.23M | 1.7 | 226,308 | -4.23% | -$54,400.02 | 0.06 |